| Literature DB >> 25361806 |
Susan O'Brien, Jerald P Radich, Camille N Abboud, Mojtaba Akhtari, Jessica K Altman, Ellin Berman, Peter Curtin, Daniel J DeAngelo, Michael Deininger, Steven Devine, Amir T Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O Moore, Arnel Pallera, Vishnu Vb Reddy, Neil P Shah, B Douglas Smith, David S Snyder, Meir Wetzler, Kristina Gregory, Hema Sundar.
Abstract
Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25361806 DOI： 10.6004/jnccn.2014.0159
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908